RU2727805C2 - Аминопиразиновые соединения со свойствами антагониста a2a - Google Patents
Аминопиразиновые соединения со свойствами антагониста a2a Download PDFInfo
- Publication number
- RU2727805C2 RU2727805C2 RU2017120853A RU2017120853A RU2727805C2 RU 2727805 C2 RU2727805 C2 RU 2727805C2 RU 2017120853 A RU2017120853 A RU 2017120853A RU 2017120853 A RU2017120853 A RU 2017120853A RU 2727805 C2 RU2727805 C2 RU 2727805C2
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- amino
- carboxamide
- pyrazine
- oxazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081262P | 2014-11-18 | 2014-11-18 | |
| US62/081,262 | 2014-11-18 | ||
| PCT/US2015/060509 WO2016081290A1 (en) | 2014-11-18 | 2015-11-13 | Aminopyrazine compounds with a2a antagonist properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017120853A RU2017120853A (ru) | 2018-12-19 |
| RU2017120853A3 RU2017120853A3 (enExample) | 2019-06-17 |
| RU2727805C2 true RU2727805C2 (ru) | 2020-07-24 |
Family
ID=56014406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017120853A RU2727805C2 (ru) | 2014-11-18 | 2015-11-13 | Аминопиразиновые соединения со свойствами антагониста a2a |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10472347B2 (enExample) |
| EP (1) | EP3220910B1 (enExample) |
| JP (2) | JP6779204B2 (enExample) |
| KR (1) | KR20170083136A (enExample) |
| CN (1) | CN107106558A (enExample) |
| AU (1) | AU2015350315B2 (enExample) |
| BR (1) | BR112017010261A2 (enExample) |
| CA (1) | CA2967944C (enExample) |
| MX (1) | MX381180B (enExample) |
| RU (1) | RU2727805C2 (enExample) |
| WO (1) | WO2016081290A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311645B2 (en) * | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CN108570054B (zh) * | 2017-03-07 | 2021-07-16 | 广州再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| JP2020527588A (ja) * | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| JP2020532541A (ja) | 2017-08-31 | 2020-11-12 | コーバス・ファーマシューティカルズ・インコーポレイテッド | アデノシンａ２ｂ受容体およびアデノシンａ２ａ受容体を調節するための化合物および方法 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| US11498923B2 (en) | 2017-12-13 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted imidazo[1,2-c]quinazolines as A2A antagonists |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| SG11202101486RA (en) | 2018-08-16 | 2021-03-30 | Innate Tumor Immunity Inc | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
| US20200079793A1 (en) * | 2018-08-31 | 2020-03-12 | Corvus Pharmaceuticals, Inc. | Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor |
| JP2022507734A (ja) | 2018-11-20 | 2022-01-18 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換アミノトリアゾロピリミジン及びアミノトリアゾロピラジンアデノシン受容体アンタゴニスト、医薬組成物及びそれらの使用 |
| US12414952B2 (en) | 2018-11-20 | 2025-09-16 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| JP2022511778A (ja) | 2018-11-30 | 2022-02-01 | メルク・シャープ・アンド・ドーム・コーポレーション | アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用 |
| AR117164A1 (es) | 2018-11-30 | 2021-07-14 | Merck Sharp & Dohme | Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| TW202128650A (zh) * | 2019-10-11 | 2021-08-01 | 德商拜耳動物保健有限公司 | 作為殺蟲劑之新穎的雜芳基取代之吡𠯤衍生物 |
| CN111285798A (zh) * | 2020-04-09 | 2020-06-16 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺盐酸盐的合成方法 |
| CN111423364A (zh) * | 2020-05-19 | 2020-07-17 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺的合成方法 |
| EP3929189A1 (en) * | 2020-06-25 | 2021-12-29 | Bayer Animal Health GmbH | Novel heteroaryl-substituted pyrazine derivatives as pesticides |
| AU2022241754A1 (en) | 2021-03-23 | 2023-10-19 | BioAge Labs, Inc. | Inhibitors of nlrp3 inflammasome |
| CN117157278A (zh) * | 2021-03-23 | 2023-12-01 | 柏奥艾奇实验室公司 | Nlrp3炎性体的抑制剂 |
| EP4469460A1 (en) | 2022-01-28 | 2024-12-04 | Bioage Labs, Inc. | N-oxide inhibitors of nlrp3 inflammasome |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| US12516018B2 (en) * | 2023-03-30 | 2026-01-06 | Brandeis University | Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025207644A1 (en) | 2024-03-26 | 2025-10-02 | BioAge Labs, Inc. | Inhibitors of nlrp3 inflammasome |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004111033A1 (en) * | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
| US20050113387A1 (en) * | 2003-10-27 | 2005-05-26 | Fujisawa Pharmaceutical Co. Ltd. | Pyrazine derivatives and pharmaceutical use thereof |
| US20090233944A1 (en) * | 2005-03-04 | 2009-09-17 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
| US20100075989A1 (en) * | 2002-12-17 | 2010-03-25 | Astrazeneca Ab | Novel Compounds Having Selective Inhibiting Effect at GSK3 |
| US20120065205A1 (en) * | 2009-06-01 | 2012-03-15 | Mercer Swati P | Pyrazine carboxamide orexin receptor antagonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| US5565460A (en) | 1993-07-27 | 1996-10-15 | Kyowa Hakko Koygo Co., Ltd. | Therapeutic purine agents for parkinson's disease |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| PT1283839E (pt) | 2000-05-26 | 2005-08-31 | Schering Corp | Antagonistas do receptor a2a da adenosina |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
-
2015
- 2015-11-13 AU AU2015350315A patent/AU2015350315B2/en not_active Ceased
- 2015-11-13 JP JP2017526527A patent/JP6779204B2/ja not_active Expired - Fee Related
- 2015-11-13 EP EP15861650.8A patent/EP3220910B1/en active Active
- 2015-11-13 US US15/525,788 patent/US10472347B2/en active Active
- 2015-11-13 CA CA2967944A patent/CA2967944C/en not_active Expired - Fee Related
- 2015-11-13 BR BR112017010261-7A patent/BR112017010261A2/pt not_active IP Right Cessation
- 2015-11-13 RU RU2017120853A patent/RU2727805C2/ru active
- 2015-11-13 KR KR1020177016281A patent/KR20170083136A/ko not_active Withdrawn
- 2015-11-13 MX MX2017006483A patent/MX381180B/es unknown
- 2015-11-13 WO PCT/US2015/060509 patent/WO2016081290A1/en not_active Ceased
- 2015-11-13 CN CN201580073488.3A patent/CN107106558A/zh active Pending
-
2020
- 2020-08-19 JP JP2020138418A patent/JP2020193211A/ja not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075989A1 (en) * | 2002-12-17 | 2010-03-25 | Astrazeneca Ab | Novel Compounds Having Selective Inhibiting Effect at GSK3 |
| WO2004111033A1 (en) * | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
| US20050113387A1 (en) * | 2003-10-27 | 2005-05-26 | Fujisawa Pharmaceutical Co. Ltd. | Pyrazine derivatives and pharmaceutical use thereof |
| US20090233944A1 (en) * | 2005-03-04 | 2009-09-17 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
| RU2407739C2 (ru) * | 2005-03-04 | 2010-12-27 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРАЗИН-2-КАРБОКСАМИДА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR5 |
| US20120065205A1 (en) * | 2009-06-01 | 2012-03-15 | Mercer Swati P | Pyrazine carboxamide orexin receptor antagonists |
Non-Patent Citations (2)
| Title |
|---|
| CELINE BONNEFOUS et al.: "Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, vol.15, no.4, pages 1197-1200 * |
| CELINE BONNEFOUS et al.: "Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, vol.15, no.4, pages 1197-1200. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US10472347B2 (en) | 2019-11-12 |
| WO2016081290A1 (en) | 2016-05-26 |
| BR112017010261A2 (pt) | 2018-02-06 |
| CA2967944A1 (en) | 2016-05-26 |
| EP3220910A4 (en) | 2018-04-25 |
| CN107106558A (zh) | 2017-08-29 |
| MX381180B (es) | 2025-03-12 |
| CA2967944C (en) | 2020-11-17 |
| EP3220910B1 (en) | 2020-01-15 |
| RU2017120853A (ru) | 2018-12-19 |
| JP2020193211A (ja) | 2020-12-03 |
| MX2017006483A (es) | 2017-09-12 |
| RU2017120853A3 (enExample) | 2019-06-17 |
| EP3220910A1 (en) | 2017-09-27 |
| AU2015350315A1 (en) | 2017-05-18 |
| AU2015350315B2 (en) | 2020-06-25 |
| KR20170083136A (ko) | 2017-07-17 |
| JP2017533946A (ja) | 2017-11-16 |
| US20180327385A1 (en) | 2018-11-15 |
| JP6779204B2 (ja) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3220910B1 (en) | Aminopyrazine compounds with a2a antagonist properties | |
| AU2014338549B2 (en) | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | |
| EP3717488B1 (en) | Substituted furanopyrimidine compounds as pde1 inhibitors | |
| US9233977B2 (en) | Leucine-rich repeat kinase enzyme activity | |
| US9725453B2 (en) | Imidazotriazinone compounds | |
| EP3253390B1 (en) | Aminoquinazoline compounds as a2a antagonist | |
| EP3331532B1 (en) | Substituted aminoquinazoline compounds as a2a antagonist | |
| AU2016261031A1 (en) | Substituted quinoxaline derivatives | |
| KR20200022027A (ko) | 아데노신 A2A 수용체의 이미다조[1,2,a]피라진 조절물질 | |
| WO2014159591A1 (en) | Substituted 7-azabicycles and their use as orexin receptor modulators | |
| WO2016086200A9 (en) | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors | |
| JP2021533179A (ja) | ピラジン化合物およびその使用 | |
| KR20160056896A (ko) | Ｐｉｍ 키나아제 억제제로서 유용한 푸로- 및 티에노-피리딘 카복사미드 화합물 | |
| US12448368B2 (en) | Indole compounds as androgen receptor modulators | |
| WO2016168633A1 (en) | Indazolones as modulators of tnf signaling | |
| CN115181092B (zh) | 吡嗪化合物和其用途 | |
| KR20250172652A (ko) | 신경학적 및 정신의학적 장애의 치료에 유용한 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 1,6-나프티리딘 유도체 | |
| US20240270748A1 (en) | Tricyclic heterocycles | |
| RU2809631C2 (ru) | Пиразиновые соединения и их применения | |
| TW202545926A (zh) | 作為菸鹼醯胺ｎ—甲基轉移酶抑制劑的哌啶衍生物 | |
| FR3052451A1 (enExample) | ||
| HK40036192B (en) | Substituted furanopyrimidine compounds as pde1 inhibitors | |
| HK40036192A (en) | Substituted furanopyrimidine compounds as pde1 inhibitors | |
| HK1201265B (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity |